Company intelligence / Profile preview

ProTip

Ownership: Private
Development stage: Preclinical

Overview

ProTip has developed ENTegral™, the world’s first permanent implant designed to replace the larynx in patients who have undergone total laryngectomy. The device aims to restore natural breathing and improve quality of life by eliminating the need for a permanent tracheostomy. Biocompatibility and cell colonization have been validated preclinically; first-in-human clinical trials are underway or recently completed with plans for broader studies.

Therapeutic areas: OncologyOther
Modalities: DeviceImplant
Industry: Implantable Medical Devices

Partnerships

Academic partnerships with University Hospitals of Strasbourg and Insermstrong public-private alliances noted

Beyond the preview

Go deeper on ProTip.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProTip.

Explore the full profile